A multicentre, open label Phase IIIb/IV study of subcutaneously administered efalizumab in the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including cyclosporin, methotrexate and PUVA.
Latest Information Update: 19 Jan 2022
At a glance
- Drugs Efalizumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Serono S.A.
- 19 Jan 2022 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
- 11 Jul 2019 Trial has been completed in Ireland, according to European Clinical Trials Database record.
- 23 Nov 2012 New trial record